Jury Awards $88M in First Hernia Mesh Trial Against Medtronic
MDT sits 17% above its 52-week low of $73.31 on light trading volume (0.2× avg).
Summary
A federal jury awarded $88 million to an Alabama man in the first bellwether trial over hernia mesh implants made by Medtronic's Covidien unit. This is the initial verdict among thousands of pending cases, setting a potential benchmark for future settlements or judgments. The award is material but manageable for a company with a $110B market cap and $36B in annual revenue. However, the litigation risk is significant given the volume of cases. Medtronic already faces a separate $1.1B antitrust verdict under appeal, adding to legal overhang. The company has not yet commented on appeal plans for this verdict.
At the time of this announcement, MDT was trading at $85.94 on NYSE in the Life Sciences sector, with a market capitalization of approximately $110B. The 52-week trading range was $73.31 to $106.33. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.